Skip to main content
. Author manuscript; available in PMC: 2011 Dec 19.
Published in final edited form as: J Health Econ. 2011 Jun 1;30(4):695–706. doi: 10.1016/j.jhealeco.2011.05.012

Table 1.

Net monetary benefits of various CER-based subsidization policies applied to 250,000 non-elderly adult patients with schizophrenia under Medicaid.

Added QALYs over baseline Value of additional QALYS (in $B) Costs (in $B) Net monetary benefit ($B) Incremental net monetary benefit ($B)
Pre-CATIE 265,000 26.5 6.7 19.80
Partial coverage 254,000 25.4 5.9 19.30 −0.50 (vs pre-CATIE)
No coverage 251,000 25.1 5.4 19.70 0.40 (vs partial)

Notes: Partial coverage implies access only to first generation perphenazine or second generation risperidone. No coverage implies access only to first generation perphenazine. Net monetary benefits = Value of QALYs ($B) − Costs ($B).